COVID-19大流行封锁对新生血管性年龄相关性黄斑变性患者视力影响:一项大型队列研究
这项多中心回顾性研究纳入1,192例既往接受抗VEGF治疗的新生血管性年龄相关性黄斑变性(nAMD)患者,比较2019年(COVID-19前)与2020年(COVID-19期间)随访时的最佳矫正视力(BCVA)。结果显示两组基线与BCVA变化均无显著差异(P=0.342和P=0.911),但2020年抗VEGF注射次数显著低于2019年(5.55 vs 6.13,P<0.01)。基线BCVA、注射次数和年龄是最终BCVA的预测因素。
要点
- 2020年与2019年相比,nAMD患者BCVA基线与变化均无显著差异(P=0.342和P=0.911)。
- 2020年抗VEGF平均注射次数显著低于2019年(5.55 vs 6.13,P<0.01)。
- 基线BCVA、注射次数和年龄是最终BCVA的预测因素。
核心结论
- 在nAMD患者中,因COVID-19大流行封锁导致的延迟治疗对BCVA无统计学显著影响。
- 基线BCVA、年龄较大和每年抗VEGF注射次数较少是BCVA下降的预测因素。
研究设计与样本
- 多中心、回顾性研究,纳入1,192例既往接受抗VEGF注射治疗的新生血管性年龄相关性黄斑变性(nAMD)患者,平均年龄81.5岁。
- 850例在2019年(COVID-19前)接受评估,630例在2020年(COVID-19期间)接受评估,其中308例在2019年和2020年均接受评估并纳入两个队列。
主要发现
- 2020年与2019年相比,基线BCVA和BCVA变化均无显著差异(P=0.342和P=0.911)。
- 抗VEGF平均注射次数2020年显著低于2019年(5.55 vs 6.13,P<0.01),COVID-19期间每例患者注射比率持续较低。
- 基线BCVA(0.859,P<0.01)、注射次数(-0.006,P=0.01)和年龄(0.003,P<0.01)是最终BCVA的预测因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Evaluating the impact of delayed care, secondary to coronavirus disease 2019 (COVID-19) pandemic lockdowns, on visual acuity in previously treated neovascular age-related macular degeneration (nAMD) patients. METHODS: This was a multicenter, retrospective, study of patients with nAMD previously treated with anti-VEGF injections who were followed up during 2019 (pre-COVID-19) and compared with patients with nAMD during 2020 (COVID-19). RESULTS: A total of 1,192 patients with nAMD with a mean age of 81.5 years met the inclusion criteria. Of these, 850 patients were assessed in 2019 (pre-COVID-19) and 630 patients were assessed in 2020 (COVID-19). Three hundred eight patients were assessed through both 2019 and 2020 and thus were included in both cohorts. There was no significant difference between 2020 and 2019 in baseline and change in best-corrected visual acuity (BCVA; P = 0.342 and P = 0.911, respectively). The mean number of anti-VEGF injections was significantly lower (5.55 vs. 6.13, P < 0.01), with constant lower ratio of injections per patient in the COVID-19 period. Baseline BCVA (0.859, P < 0.01), number of injections (-0.006, P = 0.01), and age (0.003, P < 0.01) were predictors of final BCVA. CONCLUSION: In patients with nAMD, delayed care secondary to COVID-19 pandemic lockdowns has no statistically significant impact on BCVA. Best-corrected visual acuity, older age, and lower number of yearly anti-VEGF injections are predictors for decrease BCVA.
引用
- Shor R, Segal O, Mimouni M, et al. IMPACT OF COVID-19 PANDEMIC LOCKDOWNS ON VISUAL ACUITY OF PATIENTS WITH NEOVASCULAR AMD: A Large Cohort. Retina. 2022. PMID: 35502974. doi:10.1097/IAE.0000000000003497
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。